Mankind Pharma has inked an exclusive in-licensing and marketing agreement with China’s Chongqing Chenan Biopharmaceutical Co Ltd, to commercialise two insulin analogues - Insulin Degludec and Insulin Degludec + Aspart Combination, in India.The partnership broadens Mankind Pharma’s strategy in diabetes care and advanced injectable therapies, it said. Atish Majumdar, Mankind’s Senior President (Sales and Marketing) said in a statement, “China is rapidly emerging as a hub for innovative biopharmaceutical assets. Building on our partnerships for Insulin Aspart and Insulin Degludec, we remain focused on expanding our in-licensing pipeline from China.” The partnership with Chongqing Chenan Biopharmaceutical is aligned with Mankind Pharma’s broader strategy of leveraging global innovation through strategic partnerships and in-licensing opportunities, it added. Published on August 20, 2026